scholarly journals Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature

2017 ◽  
Vol 36 (2) ◽  
pp. 346-349 ◽  
Author(s):  
Shoichi Deguchi ◽  
Koichi Mitsuya ◽  
Yoko Nakasu ◽  
Nakamasa Hayashi ◽  
Hirohisa Katagiri ◽  
...  
Keyword(s):  
Case Report ◽  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Posterior Reversible Encephalopathy Syndrome ◽  
Kinase Inhibitor ◽  
Review Of The Literature ◽  
Posterior Reversible Encephalopathy ◽  
Reversible Encephalopathy

scholarly journals Atypical Posterior Reversible Encephalopathy Syndrome due to Oral Tyrosine Kinase Inhibitor Cabozantinib: First Case Report

2020 ◽  
Vol 13 (2) ◽  
pp. 1013-1019 ◽  
Author(s):  
Anannya Patwari ◽  
Vineel Bhatlapenumarthi ◽  
Sheila K. Pascual
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Posterior Reversible Encephalopathy Syndrome ◽  
Kinase Inhibitor ◽  
Case Reports ◽  
Cell Cancer ◽  
Mri Findings ◽  
Posterior Reversible Encephalopathy ◽  
First Case ◽  
Reversible Encephalopathy

We report here a rare case of atypical posterior reversible encephalopathy syndrome (PRES) due to oral tyrosine kinase inhibitor cabozantinib. No case reports of such have been found in our literature search. The patient, a 70-year-old female with metastatic renal cell cancer on oral tyrosine kinase inhibitor cabozantinib, was brought into the emergency room because of confusion and seizures, found to have elevated blood pressure and atypical MRI findings consistent with PRES due to cabozantinib.

scholarly journals Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the Literature

2017 ◽  
Vol 10 (1) ◽  
pp. 333-338 ◽  
Author(s):  
Yoshiro Nakahara ◽  
Tomoya Fukui ◽  
Ken Katono ◽  
Yuuki Nishizawa ◽  
Yusuke Okuma ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Lung Metastases ◽  
Case Reports ◽  
Single Agent ◽  
Review Of The Literature ◽  
Advanced Soft Tissue Sarcoma

Pazopanib, a multitargeting tyrosine kinase inhibitor, has single-agent activity in patients with advanced soft-tissue sarcoma. Herein, we describe 2 cases of pneumothorax that occurred during pazopanib treatment in patients with soft-tissue sarcoma. These 2 patients had multiple lung metastases. According to previous reports and our past experience, the risk of pneumothorax may be higher in patients with multiple lung metastases. Although a causal relationship is uncertain, the risk of pneumothorax when prescribing pazopanib for these patients should be considered.

Sign in / Sign up

Export Citation Format

Share Document